Literature DB >> 25112469

Clinical significance of HuR expression in human malignancy.

Ioly Kotta-Loizou1, Constantinos Giaginis, Stamatios Theocharis.   

Abstract

Hu-antigen R (HuR) is an RNA-binding protein that regulates the stability, translation, and nucleus-to-cytoplasm translocation of target mRNAs. The aim of the present review was to summarize and present the currently available information in the English literature on HuR expression in various human tumors, verifying its possible clinical significance. HuR function is directly linked to its subcellular localization. In normal cells, HuR is mostly localized in the nucleus, while in malignant cells, an increase in cytoplasmic HuR levels has been noted, in both cell lines and tissue samples. Moreover, in malignancy, elevated HuR expression levels and cytoplasmic immunohistochemical pattern have been correlated with advanced clinicopathological parameters and altered expression levels of proteins implicated in neoplasia. Additionally, elevated HuR expression levels and mainly cytoplasmic immunohistochemical pattern were correlated with decreased patients' survival rate in various human tumors. HuR is a putative drug target for cancer therapy, since it is expressed ubiquitously in malignant clinical samples and has an apparently consistent role in tumor formation and progression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25112469     DOI: 10.1007/s12032-014-0161-y

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  133 in total

1.  Expression of HuR in Merkel cell carcinoma and in normal skin.

Authors:  Virve Koljonen; Tom Böhling; Caj Haglund; Ari Ristimäki
Journal:  J Cutan Pathol       Date:  2008-01       Impact factor: 1.587

2.  Association between expression of embryonic lethal abnormal vision-like protein HuR and cyclooxygenase-2 in oral squamous cell carcinoma.

Authors:  Jeong-Dan Cha; ShengJin Li; In-Ho Cha
Journal:  Head Neck       Date:  2010-10-19       Impact factor: 3.147

3.  Localization of the human HuR gene to chromosome 19p13.2.

Authors:  W J Ma; H Furneaux
Journal:  Hum Genet       Date:  1997-01       Impact factor: 4.132

4.  The oncogenic RNA-binding protein Musashi1 is regulated by HuR via mRNA translation and stability in glioblastoma cells.

Authors:  Dat T Vo; Kotb Abdelmohsen; Jennifer L Martindale; Mei Qiao; Kumiko Tominaga; Tarea L Burton; Jonathan A L Gelfond; Andrew J Brenner; Vyomesh Patel; Daniel Trageser; Björn Scheffler; Myriam Gorospe; Luiz O F Penalva
Journal:  Mol Cancer Res       Date:  2012-01       Impact factor: 5.852

5.  The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis.

Authors:  Lisa E Young; Sandhya Sanduja; Kristi Bemis-Standoli; Edsel A Pena; Robert L Price; Dan A Dixon
Journal:  Gastroenterology       Date:  2009-01-15       Impact factor: 22.682

6.  Posttranscriptional regulation of the breast cancer susceptibility gene BRCA1 by the RNA binding protein HuR.

Authors:  Jodi M Saunus; Juliet D French; Stacey L Edwards; Dianne J Beveridge; Esme C Hatchell; Sarah A Wagner; Sandra R Stein; Andrew Davidson; Kaylene J Simpson; Glenn D Francis; Peter J Leedman; Melissa A Brown
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

7.  Clinicopathological significance of HuR expression in gallbladder carcinoma: with special emphasis on the implications of its nuclear and cytoplasmic expression.

Authors:  Ding-Ping Sun; Ching-Yih Lin; Yu-Feng Tian; Li-Tzong Chen; Li-Ching Lin; Sung-Wei Lee; Chung-Hsi Hsing; Hao-Hsien Lee; Yow-Ling Shiue; Hsuan-Ying Huang; Chien-Feng Li; Peir-In Liang
Journal:  Tumour Biol       Date:  2013-05-31

8.  Macrophage β2 integrin-mediated, HuR-dependent stabilization of angiogenic factor-encoding mRNAs in inflammatory angiogenesis.

Authors:  Jiange Zhang; Yasha Modi; Timur Yarovinsky; Jun Yu; Mark Collinge; Themis Kyriakides; Yizhun Zhu; William C Sessa; Ruggero Pardi; Jeffrey R Bender
Journal:  Am J Pathol       Date:  2012-02-07       Impact factor: 4.307

9.  pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs.

Authors:  Timothy K Williams; Christina L Costantino; Nikolai A Bildzukewicz; Nathan G Richards; David W Rittenhouse; Lisa Einstein; Joseph A Cozzitorto; Judith C Keen; Abhijit Dasgupta; Myriam Gorospe; Gregory E Gonye; Charles J Yeo; Agnieszka K Witkiewicz; Jonathan R Brody
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

10.  High expression of HuR in cytoplasm, but not nuclei, is associated with malignant aggressiveness and prognosis in bladder cancer.

Authors:  Yasuyoshi Miyata; Shin-ichi Watanabe; Yuji Sagara; Kensuke Mitsunari; Tomohiro Matsuo; Kojiro Ohba; Hideki Sakai
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

View more
  34 in total

1.  Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human non-small-cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.

Authors:  Constantinos Giaginis; Paraskevi Alexandrou; Nikolaos Tsoukalas; Ioannis Sfiniadakis; Nikolaos Kavantzas; Emmanuel Agapitos; Efstratios Patsouris; Stamatios Theocharis
Journal:  Tumour Biol       Date:  2014-09-25

2.  Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients.

Authors:  Constantinos Giaginis; Anastasia Sampani; Iolly Kotta-Loizou; Ioanna Giannopoulou; Eugene Danas; Ekaterini Politi; Gerasimos Tsourouflis; Gregorios Kouraklis; Efstratios Patsouris; Antonios Keramopoulos; Lydia Nakopoulou; Stamatios Theocharis
Journal:  Pathol Oncol Res       Date:  2017-08-14       Impact factor: 3.201

3.  Negative regulation of RNA-binding protein HuR by tumor-suppressor ECRG2.

Authors:  C Lucchesi; M S Sheikh; Y Huang
Journal:  Oncogene       Date:  2015-10-05       Impact factor: 9.867

4.  BOPC1 Enantiomers Preparation and HuR Interaction Study. From Molecular Modeling to a Curious DEEP-STD NMR Application.

Authors:  Serena Della Volpe; Roberta Listro; Michela Parafioriti; Marcello Di Giacomo; Daniela Rossi; Francesca Alessandra Ambrosio; Giosuè Costa; Stefano Alcaro; Francesco Ortuso; Anna K H Hirsch; Francesca Vasile; Simona Collina
Journal:  ACS Med Chem Lett       Date:  2020-01-28       Impact factor: 4.345

5.  Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer.

Authors:  Yasuyoshi Miyata; Kensuke Mitsunari; Asai Akihiro; Shin-Ichi Watanabe; Tomohiro Matsuo; Kojiro Ohba; Hideki Sakai
Journal:  Oncol Lett       Date:  2016-12-12       Impact factor: 2.967

Review 6.  Complex HuR function in pancreatic cancer cells.

Authors:  Jonathan R Brody; Dan A Dixon
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-02-16       Impact factor: 9.957

7.  The zinc finger domains in U2AF26 and U2AF35 have diverse functionalities including a role in controlling translation.

Authors:  Olga Herdt; Stefan Reich; Jan Medenbach; Bernd Timmermann; Didrik Olofsson; Marco Preußner; Florian Heyd
Journal:  RNA Biol       Date:  2020-03-01       Impact factor: 4.652

Review 8.  Post-transcriptional regulation of cytokine and growth factor signaling in cancer.

Authors:  Irina Vlasova-St Louis; Paul R Bohjanen
Journal:  Cytokine Growth Factor Rev       Date:  2016-12-02       Impact factor: 7.638

9.  Clinical Significance of Hu-Antigen Receptor (HuR) and Cyclooxygenase-2 (COX-2) Expression in Human Malignant and Benign Thyroid Lesions.

Authors:  Constantinos Giaginis; Paraskevi Alexandrou; Ioanna Delladetsima; Ioannis Karavokyros; Eugene Danas; Athina Giagini; Efstratios Patsouris; Stamatios Theocharis
Journal:  Pathol Oncol Res       Date:  2016-01       Impact factor: 3.201

10.  Circular RNA circAGO2 drives cancer progression through facilitating HuR-repressed functions of AGO2-miRNA complexes.

Authors:  Yajun Chen; Feng Yang; Erhu Fang; Wenjing Xiao; Hong Mei; Huanhuan Li; Dan Li; Huajie Song; Jianqun Wang; Mei Hong; Xiaojing Wang; Kai Huang; Liduan Zheng; Qiangsong Tong
Journal:  Cell Death Differ       Date:  2018-10-19       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.